Ishii group

Ishin Pharma is a Japanese biotechnology company focused on the development of regenerative medical products for intractable diseases. Founded in 2008, the company's lead program, ISN001, is a cell-based therapy currently in late-stage clinical development for the treatment of epidermolysis bullosa, a rare and severe hereditary skin disorder. Ishin Pharma utilizes an innovative drug discovery platform that combines mesenchymal stem cells with advanced gene transfer technology. The company maintains a strategic business alliance and investment partnership with Toho Holdings to support the manufacturing, distribution, and commercialization of its regenerative medicine portfolio. Its research efforts are bolstered by collaborations with leading academic experts in gene therapy and cell biology.